Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Peter Michael Ellis; Geoffrey Liu; Michael Millward; Francesco Perrone; Frances A. Shepherd; Sophie Sun; Byoung Chul Cho; Alessandro Morabito; Martin R. Stockier; Rafal Wierzbicki; Victor Cohen; Normand Blais; Randeep S. Sangha; Adolfo G. Favaretto; Jin Hyoung Kang; Carolyn F. Wilson; Joseph O'Connell; Keyue Ding; Glenwood D. Goss; Penelope Ann Bradbury

doi:10.1200/jco.2014.32.15_suppl.8036

Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

Peter Michael Ellis
, Geoffrey Liu
, Michael Millward
, Francesco Perrone
, Frances A. Shepherd
, Sophie Sun
, Byoung Chul Cho
, Alessandro Morabito
, Martin R. Stockier
, Rafal Wierzbicki
, Victor Cohen
, Normand Blais
, Randeep S. Sangha
, Adolfo G. Favaretto
, Jin Hyoung Kang
, Carolyn F. Wilson
, Joseph O'Connell
, Keyue Ding
, Glenwood D. Goss
, Penelope Ann Bradbury

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	32
Issue number	15
DOIs	https://doi.org/10.1200/jco.2014.32.15_suppl.8036
Publication status	Published - 20 May 2014
Externally published	Yes
Event	50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States Duration: 30 May 2014 → 3 Jun 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1200/jco.2014.32.15_suppl.8036

Cite this

Ellis, P. M., Liu, G., Millward, M., Perrone, F., Shepherd, F. A., Sun, S., Cho, B. C., Morabito, A., Stockier, M. R., Wierzbicki, R., Cohen, V., Blais, N., Sangha, R. S., Favaretto, A. G., Kang, J. H., Wilson, C. F., O'Connell, J., Ding, K., Goss, G. D., & Bradbury, P. A. (2014). Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. Journal of Clinical Oncology, 32(15). https://doi.org/10.1200/jco.2014.32.15_suppl.8036

@article{fab97ee384ca4f39af28f2d6e71b3dab,

title = "Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.",

author = "Ellis, \{Peter Michael\} and Geoffrey Liu and Michael Millward and Francesco Perrone and Shepherd, \{Frances A.\} and Sophie Sun and Cho, \{Byoung Chul\} and Alessandro Morabito and Stockier, \{Martin R.\} and Rafal Wierzbicki and Victor Cohen and Normand Blais and Sangha, \{Randeep S.\} and Favaretto, \{Adolfo G.\} and Kang, \{Jin Hyoung\} and Wilson, \{Carolyn F.\} and Joseph O'Connell and Keyue Ding and Goss, \{Glenwood D.\} and Bradbury, \{Penelope Ann\}",

year = "2014",

month = may,

day = "20",

doi = "10.1200/jco.2014.32.15\_suppl.8036",

language = "English",

volume = "32",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "15",

note = "50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ASCO ; Conference date: 30-05-2014 Through 03-06-2014",

}

Ellis, PM, Liu, G, Millward, M, Perrone, F, Shepherd, FA, Sun, S, Cho, BC, Morabito, A, Stockier, MR, Wierzbicki, R, Cohen, V, Blais, N, Sangha, RS, Favaretto, AG, Kang, JH, Wilson, CF, O'Connell, J, Ding, K, Goss, GD & Bradbury, PA 2014, 'Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.', Journal of Clinical Oncology, vol. 32, no. 15. https://doi.org/10.1200/jco.2014.32.15_suppl.8036

Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. / Ellis, Peter Michael; Liu, Geoffrey; Millward, Michael et al.
In: Journal of Clinical Oncology, Vol. 32, No. 15, 20.05.2014.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Ncic Ctg Br.26

T2 - 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

AU - Ellis, Peter Michael

AU - Liu, Geoffrey

AU - Millward, Michael

AU - Perrone, Francesco

AU - Shepherd, Frances A.

AU - Sun, Sophie

AU - Cho, Byoung Chul

AU - Morabito, Alessandro

AU - Stockier, Martin R.

AU - Wierzbicki, Rafal

AU - Cohen, Victor

AU - Blais, Normand

AU - Sangha, Randeep S.

AU - Favaretto, Adolfo G.

AU - Kang, Jin Hyoung

AU - Wilson, Carolyn F.

AU - O'Connell, Joseph

AU - Ding, Keyue

AU - Goss, Glenwood D.

AU - Bradbury, Penelope Ann

PY - 2014/5/20

Y1 - 2014/5/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000358613204101&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/jco.2014.32.15_suppl.8036

DO - 10.1200/jco.2014.32.15_suppl.8036

M3 - Abstract/Meeting Abstract

SN - 0732-183X

VL - 32

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

Y2 - 30 May 2014 through 3 June 2014

ER -

Ellis PM, Liu G, Millward M, Perrone F, Shepherd FA, Sun S et al. Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. Journal of Clinical Oncology. 2014 May 20;32(15). doi: 10.1200/jco.2014.32.15_suppl.8036

Ncic Ctg Br.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.

UN SDGs

Access to Document

Other files and links

Cite this